Solgate GmbH was successfully awarded a Seed grant from the Austria Wirtschaftsservice (AWS) to further develop its chemoproteomics platform geared towards the identification of new compounds targeting solute carriers (SLCs). The grant follows up the successful award of a pre-seed grant in 2021, which provided initial support to the platform development. As part of these efforts, Solgate will establish a mass-spectrometry-based pipeline to systematically identify small molecules able to bind to SLC proteins that could act as chemical starting points for future drug discovery programs.

Chemoproteomics approaches based on functionalized fragments are a recent and highly scalable technology that allows for the systematic identification of fragment– protein interactions while keeping the target proteins in their native cellular environment. This approach has shown particular promise when applied to SLC proteins and will complement the metabolism- and image-based approaches currently under development at Solgate.

For more information, contact: office@solgate.com

Solgate GmbH pursues the development of drugs modulating the activity of SLC proteins, focusing on the important roles of SLCs in neurological, autoimmune, and metabolic disorders. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs. Solgate GmbH was founded by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino, together with CeMM and IST Austria.